90% of Stock Market Returns Come From THIS
If you haven't yet grabbed your free copy of the Ultimate Dividend Package, you're missing out.

For starters: It's FREE. But more importantly...90% of the stock market's returns over the past century have come from dividends.
Click here to see how to grab your copy now.
Margaret G. Mcglynn, insider at Amicus Therapeutics
Margaret G. Mcglynn Insider Alerts

Get notified the next time Margaret G. Mcglynn buys or sells Amicus Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Margaret G. Mcglynn Insider Information

Director of Amicus Therapeutics
Margaret G. McGlynn has served as a member of our Board since October 2009. She retired from Merck after 26 years including roles as President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales and managed care. Following her retirement from Merck, Ms. McGlynn served as CEO and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn serves as a member of the Board of Directors of Vertex Pharmaceuticals, Inc. and of Novavax, Inc. She also serves on the Board of Buffalo BioNet Advisory Group (private) and the Board of the Advisory Committee, UB School of Pharmacy (private). Previously, she served on the Boards of Air Products and Chemicals, Inc. and Orphan Technologies. She is also Chair of the Board of HCU Network America, a non‑profit which provides advocacy and support research for patients affected by the rare disease homocystinuria. Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo.

Ms. McGlynn serves as chair of the Compensation and Leadership Development Committee and as member of the Nominating and Governance Committee.

What is Margaret G. Mcglynn's net worth?

The estimated net worth of Margaret G. Mcglynn is at least $349,233.99 as of May 3rd, 2021. Ms. Mcglynn owns 37,919 shares of Amicus Therapeutics stock worth more than $349,234 as of January 20th. This net worth approximation does not reflect any other assets that Ms. Mcglynn may own. Learn More.

How do I contact Margaret G. Mcglynn?

The corporate mailing address for Ms. Mcglynn and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]

Has Margaret G. Mcglynn been buying or selling shares of Amicus Therapeutics?

Margaret G. Mcglynn has not been actively trading shares of Amicus Therapeutics over the course of the past ninety days. Most recently, Margaret G. Mcglynn sold 10,000 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $10.27, for a transaction totalling $102,700.00. Following the completion of the sale, the director now directly owns 37,919 shares of the company's stock, valued at $389,428.13.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (COO), Bradley Campbell (COO), John Crowley (CEO), John Crowley (CEO), Margaret Mcglynn (Director), Samantha Prout (Insider), and Burke Whitman (Director).

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, Amicus Therapeutics insiders bought shares 8 times. They purchased a total of 39,105 shares worth more than $354,377.70. During the last year, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 569,658 shares worth more than $6,693,258.28. The most recent insider tranaction occured on January, 18th when CEO John F Crowley sold 8,564 shares worth more than $87,609.72. Insiders at Amicus Therapeutics own 2.5 % of the company.

Information on this page was last updated on 1/18/2022.

Margaret G. Mcglynn Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2021Sell10,000$10.27$102,700.0037,919View SEC Filing Icon  
4/17/2020Sell10,000$11.00$110,000.0032,064View SEC Filing Icon  
1/9/2020Sell20,000$10.00$200,000.0042,064View SEC Filing Icon  
5/16/2018Sell10,000$16.00$160,000.0025,814View SEC Filing Icon  
11/10/2015Buy10,000$10.27$102,700.0010,000View SEC Filing Icon  
See Full Table

Margaret G. Mcglynn Buying and Selling Activity at Amicus Therapeutics

This chart shows Margaret G Mcglynn's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.
Read More

Today's Range

Now: $9.21
Low: $9.18
High: $9.91

50 Day Range

MA: $11.04
Low: $9.21
High: $12.48

2 Week Range

Now: $9.21
Low: $8.40
High: $21.34


2,238,868 shs

Average Volume

4,022,053 shs

Market Capitalization

$2.57 billion

P/E Ratio


Dividend Yield



Say Goodbye to Your Smartphone
According to Microsoft engineer Alex Kipman, “Smartphones are yesterday's news. The phone is already dead. People just haven't realized.”

And it’s all thanks to the device inside this black box…
Click here to see it in action.